Clarification about using Angiotensin – receptor Blockers (ARBs)

<p align="justify"><br />
Further to the previous communication on SFDA website dated 7 Shaban 1432H (8 July 2011) regarding the news published on some newspapers related to safety and security issues of using Angiotensin – receptor Blockers (ARBs) and its relation with the risk of developing cancer, where ARBs are used to control high blood pressure, heart failure and diabetic kidney disorders ( <a>click here to view ARBs registered in the Kingdom</a>)<br />
USFDA has studied this relation and analyzed 31 clinical studies which covered 150,000 patients to investigate the risk of developing cancer in ARBs users , in comparison with other blood pressure controllers. The study concluded that no connection exists between using ARBs and developing Cancer<br />
In the other hand, three recent studies revealed that there is no relation between using ARBs and the risk of developing Cancer, thus supporting the results of the study conducted by USFDA<br />
SFDA has called drug users and health care professionals to cooperate with it through reporting of any drug side effects to the National Pharmacovigilence Center via e-mail of free mail to the following address:<br />
The National Pharmacovigilence Center<br />
Drug Sector – SFDA<br />
3292 Northern Ring Road – Al Nafal Section<br />
Riyadh 13312 -6288<br />
Kingdom of Saudi Arabia<br />
Phone: 012759222 Extensions. 2356, 2354, 2317, 2353, 2334.<br />
Fax: 012057662<br />
Web Portal: <a href="http://dpic.sfda.gov.sa/">www.sfda.gov.sa/NPC</a></p&gt;